Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. izņemot tikko diagnosticēta cml hroniskā fāzē, nav kontrolētos pētījumos, kas liecina par klīnisko ieguvumu vai palielina izdzīvošanas šo slimību. .

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - cits, 1320g vai 600g, vai 33g - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - pulveris - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - cits, batoniņš - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - cits, konfekte - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - cits, batoniņš - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zviedri, sia 40003126816 pavasara gatve 1/3, rīga, lv-1082 - pulveris - cits - pārtikas produkts, kas paredzēts intensīvas muskuļu piepūles gadījumos, īpaši sportistiem

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

pharmatech a.s. - tablete

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Latvija - latviešu - Ecolab

ecolab deutschland gmbh -